Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 8/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923439 | 0.91 | PDE5A (0.48) | PDE5APTK2JAK1JAK3LRRK2 | |
| SCHEMBL4920898 | 0.87 | PDE5A (0.45) | PDE5APTK2JAK1JAK3BRD4 | |
| SCHEMBL4916910 | 0.87 | LRRK2 (0.50) | PTK2JAK1JAK3LRRK2BRD4 | |
| SCHEMBL4914661 | 0.83 | PTK2 (0.43) | PTK2JAK1JAK3LRRK2BRD4 | |
| SCHEMBL4914810 | 0.83 | PTK2 (0.41) | PTK2JAK1JAK3LRRK2BRD4 | |
| SCHEMBL4914819 | 0.82 | PDE5A (0.44) | PDE5APTK2JAK1JAK3BRD4 | |
| SCHEMBL4916374 | 0.82 | PDE5A (0.50) | PDE5APTK2 | |
| SCHEMBL4913669 | 0.82 | JAK3 (0.40) | PTK2JAK1JAK3LRRK2BRD4 | |
| SCHEMBL4917778 | 0.82 | BRD4 (0.38) | PDE5APTK2JAK1JAK3LRRK2 | |
| SCHEMBL4916387 | 0.82 | PTK2 (0.41) | PTK2JAK1JAK3LRRK2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | PDE5A 1383/4885PTK2 1036/4885JAK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.